X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (77) 77
index medicus (75) 75
neuroblastoma (74) 74
immunotherapy (67) 67
anti-gd2 antibody (65) 65
oncology (56) 56
cancer (37) 37
animals (34) 34
gangliosides - immunology (34) 34
phase-i trial (32) 32
colony-stimulating factor (31) 31
antibodies, monoclonal - therapeutic use (29) 29
children (27) 27
child (26) 26
tumors (26) 26
gangliosides (25) 25
neuroblastoma - therapy (25) 25
immunology (24) 24
high-risk neuroblastoma (22) 22
neuroblastoma - drug therapy (22) 22
pediatrics (22) 22
therapy (22) 22
female (20) 20
monoclonal antibodies (20) 20
mice (19) 19
care and treatment (18) 18
cell line, tumor (18) 18
cytotoxicity (18) 18
monoclonal-antibody (18) 18
anti-gd2 monoclonal-antibody (17) 17
article (17) 17
chemotherapy (16) 16
child, preschool (16) 16
male (16) 16
neuroblastoma - immunology (16) 16
antitumor-activity (15) 15
melanoma (14) 14
neuroblastoma - pathology (14) 14
stage 4 neuroblastoma (14) 14
antigens (13) 13
ch14.18 (13) 13
gangliosides - metabolism (13) 13
gd2 (13) 13
pharmacology & pharmacy (13) 13
research (13) 13
solid tumors (13) 13
treatment outcome (13) 13
apoptosis (12) 12
bone-marrow-transplantation (12) 12
combined modality therapy (12) 12
ganglioside gd2 (12) 12
infant (12) 12
antibodies (11) 11
antibodies, monoclonal - adverse effects (11) 11
antibodies, monoclonal - pharmacology (11) 11
antibody (11) 11
immunotherapy - methods (11) 11
interleukin-2 (11) 11
t-cells (11) 11
adolescent (10) 10
analysis (10) 10
anti-gd2 (10) 10
antibodies, monoclonal - administration & dosage (10) 10
antibodies, monoclonal - immunology (10) 10
health aspects (10) 10
immune system (10) 10
immunoglobulins (10) 10
phase-i (10) 10
tumor cells, cultured (10) 10
adult (9) 9
antigen (9) 9
antineoplastic agents - therapeutic use (9) 9
clinical trials (9) 9
natural-killer-cells (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cell biology (8) 8
childrens oncology group (8) 8
flow cytometry (8) 8
hematology (8) 8
medicine & public health (8) 8
medicine, research & experimental (8) 8
melanoma - immunology (8) 8
natural killer cells (8) 8
neoplasms - drug therapy (8) 8
neuroblastoma - metabolism (8) 8
refractory neuroblastoma (8) 8
transplantation (8) 8
viral antibodies (8) 8
antineoplastic agents - administration & dosage (7) 7
growth (7) 7
lymphocytes (7) 7
medical research (7) 7
metastatic melanoma (7) 7
monoclonal-antibodies (7) 7
pain (7) 7
research article (7) 7
review (7) 7
risk factors (7) 7
stem-cell transplantation (7) 7
t-lymphocytes - immunology (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Cellular Physiology, ISSN 0021-9541, 02/2018, Volume 233, Issue 2, pp. 866 - 879
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 06/2017, Volume 255, pp. 108 - 119
Neuroblastoma is a pediatric solid tumor with high expression of the tumor associated antigen disialoganglioside GD2. Despite initial response to induction... 
Microdialysis | Irinotecan/SN-38 | Tumor extracellular fluid | GD2-targeted nanoparticles | Intratumor drug distribution | Neuroblastoma | PDX models | TOPOISOMERASE-I INHIBITOR | MOUSE | ANTI-GD2 ANTIBODY | CANCER | CHEMISTRY, MULTIDISCIPLINARY | DELIVERY | GD2 | IMMUNOTHERAPY | THERAPEUTIC TARGET | IRINOTECAN | PHARMACOLOGY & PHARMACY | MICE | Camptothecin - chemistry | Nanoparticles - chemistry | Humans | Gene Expression Regulation, Neoplastic | Child, Preschool | Male | Tissue Distribution | Antineoplastic Agents, Phytogenic - administration & dosage | N-Acetylgalactosaminyltransferases - genetics | Antigens, Neoplasm - metabolism | Camptothecin - administration & dosage | N-Acetylgalactosaminyltransferases - metabolism | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antibodies, Monoclonal - chemistry | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Antigens, Neoplasm - genetics | Immunoglobulin G - chemistry | Antineoplastic Agents, Phytogenic - chemistry | Immunoglobulin G - administration & dosage | Xenograft Model Antitumor Assays | Extracellular Fluid - metabolism | Animals | Antibodies, Monoclonal - administration & dosage | Mice, Nude | N-Acetylgalactosaminyltransferases - immunology | Neuroblastoma - drug therapy | Cell Line, Tumor | Drug Liberation | Nanoparticles - administration & dosage | Neuroblastoma - metabolism | N-Acetylgalactosaminyltransferases - antagonists & inhibitors | Drugs | Nanoparticles | Antigens | Drug delivery systems | Biological products | Drug wholesalers | Monoclonal antibodies | Drug therapy | Gangliosides | Tumors | Vehicles | SN-38 | irinotecan | microdialysis | intratumor drug distribution | neuroblastoma | tumor extracellular fluid
Journal Article
Expert Review of Pharmacoeconomics and Outcomes Research, ISSN 1473-7167, 04/2015, Volume 15, Issue 2, pp. 331 - 340
Introduction: Mepact (R) (mifamurtide) is the first drug approved for the treatment of high-grade resectable non-metastatic osteosarcoma in patients aged 2-30... 
QALY | cost-effectiveness | mifamurtide | orphan drug | pharmacoeconomics | osteosarcoma | SURVIVAL | ANTI-GD2 ANTIBODY | NEUROBLASTOMA | CANCER | TUMORS | CHEMOTHERAPY | CHILDREN | THERAPY | ADOLESCENTS | HEALTH CARE SCIENCES & SERVICES | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | MURAMYL TRIPEPTIDE
Journal Article
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 2/2013, Volume 47, Issue 2, pp. 210 - 218
OBJECTIVE: To systematically review clinical trials evaluating anti-disialoganglioside (GD2) antibodies in treating high-risk neuroblastoma in children. DATA... 
COLONY-STIMULATING FACTOR | REFRACTORY NEUROBLASTOMA | BONE-MARROW-TRANSPLANTATION | 13-CIS-RETINOIC ACID | PHARMACOLOGY & PHARMACY | ANTI-GD2 ANTIBODY | CANCER GROUP | PHASE-I | STAGE 4 NEUROBLASTOMA | CHILDRENS ONCOLOGY GROUP | CHIMERIC ANTI-GD2-ANTIBODY CH14.18 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | United States | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drugs, Investigational - therapeutic use | Antibodies, Monoclonal - therapeutic use | Risk | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Gangliosides - metabolism | Antineoplastic Agents - pharmacology | Child | Antibodies, Monoclonal, Humanized - adverse effects | Gangliosides - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - therapeutic use | Antibodies, Monoclonal - pharmacology | Clinical Trials as Topic | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Drugs, Investigational - administration & dosage | Neuroblastoma - metabolism
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 03/2015, Volume 19, Issue 3, pp. 349 - 362
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 13, pp. 3929 - 3941
Journal Article
Journal Article